Cryptococcus neoformans/gattii Species Complexes from Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B

References

• Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2012;9:e1001316. doi:10.1371/journal.pmed.100131623055838
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv113. doi:10.1126/scitranslmed.3004404
   Web of Science ®Google Scholar
• Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J. 2001;77:769–773. doi:10.1136/pmj.77.914.76911723315
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist Updat. 1999;2:259–269. doi:10.1054/drup.1999.009011504497
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322. doi:10.1086/64985820047480
   PubMed Web of Science ®Google Scholar
• Bongomin F, Oladele RO, Gago S, Moore CB, Richardson MD. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018;61:290–297. doi:10.1111/myc.1274729377368
   PubMed Web of Science ®Google Scholar
• Pappas PG. Antifungal trials: progress, approaches, new targets, and perspectives in cryptococcosis In: Heitman J, Kozel T, Kwon-Chung K, Perfect J, editors. Cryptococcus from Human Pathogen to Model Yeast. Washington (DC): American Society of Microbiology; 2011:527–536.
   Google Scholar
• Mlinaric-Missoni E, Hagen F, Chew WH, Vazic-Babic V, Boekhout T, Begovac J. In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia. J Med Microbiol. 2011;60:1487–1495. doi:10.1099/jmm.0.031344-021617022
   PubMed Web of Science ®Google Scholar
• Chandenier J, Adou-Bryn KD, Douchet C, et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis. 2004;23:506–508. doi:10.1007/s10096-004-1136-215141336
   PubMed Web of Science ®Google Scholar
• Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J Antimicrob Chemother. 2003;52:683–686. doi:10.1093/jac/dkg39912951350
   PubMed Web of Science ®Google Scholar
• Chen YC, Chang TY, Liu JW, et al. Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. BMC Infect Dis. 2015;15:277. doi:10.1186/s12879-015-1023-826194004
   PubMed Web of Science ®Google Scholar
• Soogarun S, Wiwanitkit V, Palasuwan A, et al. Detection of Cryptococcus neoformans in bird excreta. Southeast Asian J Trop Med Public Health. 2006;37:768–770.17121304
   PubMedGoogle Scholar
• Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol. 2015;78:16–48. doi:10.1016/j.fgb.2015.02.00925721988
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Iqbal N, Bolden CB, et al. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis. 2012;73:144–148. doi:10.1016/j.diagmicrobio.2012.02.01822494557
   PubMed Web of Science ®Google Scholar
• Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses. 2006;49:324–330. doi:10.1111/j.1439-0507.2006.01242.x16784448
   PubMed Web of Science ®Google Scholar
• Andrade-Silva L, Ferreira-Paim K, Mora DJ, et al. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil. Med Mycol. 2013;51:635–640. doi:10.3109/13693786.2012.76173723343452
   PubMed Web of Science ®Google Scholar
• CLSI. Epidemiological Cutoff Values for Antifungal Susceptibility Testing, CLSI Suppl M59 Document. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Danesi P, Firacative C, Cogliati M, Otranto D, Capelli G, Meyer W. Multilocus sequence typing (MLST) and M13 PCR fingerprinting revealed heterogeneity amongst Cryptococcus species obtained from Italian veterinary isolates. FEMS Yeast Res. 2014;14:897–909. doi:10.1111/1567-1364.1217824981157
   PubMed Web of Science ®Google Scholar
• CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th Suppl., M27-S4. Wayne (PA): Clinical Laboratory Standards Institute; 2012.
   Google Scholar
• Bennett JE. Susceptibility of Cryptococcus neoformans to amphotericin B. Antimicrob Agents Chemother (Bethesda). 1966;6:405–410.5985264
   PubMedGoogle Scholar
• Meyer W, Aanensen DM, Boekhout T, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 2009;47:561–570. doi:10.1080/1369378090295388619462334
   PubMed Web of Science ®Google Scholar
• Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, IberoAmerican Cryptococcal Study G. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003;9:189–195. doi:10.3201/eid0902.02024612603989
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev. 2001;14:643–658. doi:10.1128/cmr.14.4.643-658.200111585779
   PubMed Web of Science ®Google Scholar
• Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother. 2000;44:1544–1548. doi:10.1128/aac.44.6.1544-1548.200010817706
   PubMed Web of Science ®Google Scholar
• Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000;1:287–304. doi:10.1517/14656566.1.2.28711249550
   PubMedGoogle Scholar
• Pan W, Khayhan K, Hagen F, et al. Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. PLoS One. 2012;7:e32868. doi:10.1371/journal.pone.003286822427900
   PubMed Web of Science ®Google Scholar
• Hagen F, Hare Jensen R, Meis JF, Arendrup MC. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses. 2016;59:576–584. doi:10.1111/myc.1250727061834
   PubMed Web of Science ®Google Scholar
• Worasilchai N, Tangwattanachuleeporn M, Meesilpavikkai K, et al. Diversity and antifungal drug susceptibility of cryptococcus isolates in Thailand. Med Mycol. 2017;55:680–685. doi:10.1093/mmy/myw13027915307
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Randhawa HS, Sundar G, et al. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol. 2011;60:961–967. doi:10.1099/jmm.0.029025-021393452
   PubMed Web of Science ®Google Scholar
• Pfaller M, Zhang J, Messer S, et al. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. Diagn Microbiol Infect Dis. 1998;32:191–199. doi:10.1016/S0732-8893(98)00095-99884835
   PubMed Web of Science ®Google Scholar
• Franzot SP, Hamdan JS. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother. 1996;40:822–824. doi:10.1128/AAC.40.3.8228851624
   PubMed Web of Science ®Google Scholar
• Archibald LK, Tuohy MJ, Wilson DA, et al. Antifungal susceptibilities of Cryptococcus neoformans. Emerg Infect Dis. 2004;10:143–145. doi:10.3201/eid1001.02077915078612
   PubMed Web of Science ®Google Scholar
• Trilles L, Fernandez-Torres B, Lazera Mdos S, Wanke B, Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol. 2004;42:4815–4817. doi:10.1128/jcm.42.10.4815-4817.200415472349
   PubMed Web of Science ®Google Scholar
• Chen YC, Chang SC, Shih CC, et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis. 2000;36:175–183. doi:10.1016/S0732-8893(99)00137-610729660
   PubMed Web of Science ®Google Scholar
• Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515–548. doi:10.1128/CMR.8.4.5158665468
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Jones RN, Castanheira M. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). J Antibiot (Tokyo). 2015;68:556–561. doi:10.1038/ja.2015.2925899126
   PubMed Web of Science ®Google Scholar
• Selb R, Fuchs V, Graf B, et al. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017. Int J Med Microbiol. 2019;309:151336. doi:10.1016/j.ijmm.2019.15133631444102
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother. 2012;56:3107–3113. doi:10.1128/AAC.06252-1122391546
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy EM, Lyman CA, Walsh TJ. Amphotericin B: polyene resistance mechanisms In: Mayers DL, editor. Antimicrobial Drug Resistance: Mechanisms of Drug Resistance. Totowa, NJ: Humana Press; 2009:295–305.
   Google Scholar
• Herkert PF, Meis JF, Lucca de Oliveira Salvador G, et al. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. J Med Microbiol. 2018;67:560–569. doi:10.1099/jmm.0.00069829461182
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Aller AI, Canton E, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012;56:5898–5906. doi:10.1128/aac.01115-1222948877
   PubMed Web of Science ®Google Scholar
• Chong HS, Dagg R, Malik R, Chen S, Carter D. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol. 2010;48:4115–4120. doi:10.1128/jcm.01271-1020844209
   PubMed Web of Science ®Google Scholar
• Iqbal N, DeBess EE, Wohrle R, et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol. 2010;48:539–544. doi:10.1128/jcm.01505-0920007380
   PubMed Web of Science ®Google Scholar